A Wild Ride: Biotech Financial and M&A Trends 2014

Peter Young, President and Managing Director of Young & Partners, shares details from their “Biotech Strategic, M&A, and Financial Trends Report” for 2014. Here he examines 2014’s business, M&A, and debt and equity financing trends and predicts biotech’s future outlook.

Business:

Biotechnology company innovation has been very successful in important mainstream and niche markets and continues to outperform the pace of pharmaceutical companies.

M&A Activity:

Biotech M&A dollar volume has increased, but the number of completed deals has remained the same. In 2013 there were 27 deals worth $7.1B and in 2014 there were 27 biotech M&A deals worth $12.7B.

Debt and Equity Financing:

Equity issuance in 2014 was 167 offerings worth $14.1B, an all-time record. The IPO market has also been strong with 72 IPOs in 2014 totaling $5.7 billion, the highest in biotech history.

Future:

The capabilities of biotech companies will continue to be positive as the industry grows. Additionally, biotech M&A, IPO, and venture funding will continue to be strong and active.
Read more at PharmaExec.com…